Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
NCT07097207
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Relapsed/Refractory B-cell Lymphoma
Interventions
COMBINATION_PRODUCT:
CAR-T cell
Sponsor
Shenzhen University General Hospital